Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study

Oude Elberink, H. N. G., Jalving, M., Dijkstra, H. & van de Ven, A. A. J. M., 2020, In : Clinical and translational allergy. 10, p. 5

Research output: Contribution to journalArticleAcademicpeer-review

Carboplatin administration can usually be safely continued via a so-called desensitisation protocol when hypersensitivity reactions arise. Severe break-through reactions that occur early during desensitisation are likely to be IgE-mediated; in that case, addition of omalizumab premedication should be strongly considered.

Original languageEnglish
Pages (from-to)5
JournalClinical and translational allergy
Publication statusPublished - 2020

ID: 117064008